Our technology is built on a well understood gene delivery system
kelonia uses an advanced lentiviral vector (LVV) engineered for specific and efficient systemic delivery. This is achieved by introducing a targeting molecule that uniquely defines our LVV’s specificity while an optimized fusogen enables efficient delivery of therapeutic transgenes to the target cell. Only the vector envelope is modified, maintaining safe and durable gene delivery, as demonstrated in thousands of patients treated with LVV-modified cells.